A28 Therapeutics
La Jolla, US · Founded 2021 · Delaware corporation
A28 Therapeutics develops a targeted oncolytic peptide platform for treating multiple cancer types, with its lead candidate AT-101 in late-stage development for metastatic ovarian cancer with liver metastases and hepatocellular carcinoma. The company is also exploring combinations of AT-101 with immuno-oncology drugs and chemotherapy.
Founders & leadership
A28 Therapeutics was founded in 2021 by Stanley Lewis.
SL
Stanley LewisinFounder and CEO
Board
RB
ROSS BARRETTBoard director
Reported raises · per SEC filings
Form D private placements$1.9M disclosed across 1 round · 2022
▶$1.9MraisedJan 2025 · 26 investors · Other TechnologyRule 506(b)
▶$1.9MraisedJan 2025 · 26 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- STANLEY LEWISExecutive Officer, Director
- ROSS BARRETTDirector
- Offering amount
- $1.9M
- Amount sold
- $1.9M
- First sale
- Feb 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapBioworld12 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
A2 Biotherapeutics9 shared keywordsA2 Biotherapeutics develops cell therapy technology using the Tmod platform, which applies quantitative drug discovery methods to treat cancer patients.
AN2 Therapeutics9 shared keywordsAN2 Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs from its boron chemistry platform, with a pipeline spanning hematologic diseases, infectious diseases, oncology, and bone disorders. It targets diseases with significant unmet medical needs.
Companies competing with A28 Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does A28 Therapeutics do?
- A28 Therapeutics develops a targeted oncolytic peptide platform for treating multiple cancer types, with its lead candidate AT-101 in late-stage development for metastatic ovarian cancer with liver metastases and hepatocellular carcinoma. The company is also exploring combinations of AT-101 with immuno-oncology drugs and chemotherapy.
- Who founded A28 Therapeutics?
- A28 Therapeutics was founded by Stanley Lewis in 2021.
- How much funding has A28 Therapeutics raised?
- A28 Therapeutics has disclosed $1.9M raised across 1 round.
- Where is A28 Therapeutics headquartered?
- A28 Therapeutics is headquartered in La Jolla, US.